Hey, Joe, I've read all the GNBT/NGIO 8-Ks and
Post# of 36536
(Total Views: 524)
Posted On: 06/06/2021 11:52:22 PM
Hey, Joe,
I've read all the GNBT/NGIO 8-Ks and 10Ks/Qs in the last 3+ years. And I've also discussed this with some of the brightest shareholder minds involved in GNBT. No one understands it. Riddle me this, and I do hope you have a legitimate explanation that proves me wrong.
How can you offer China Excellagen rights in the event of a CV vaccine failure as part of the 2nd deal, when this is what I can find on the rights acquisition chain for Excellagen:
"SAN DIEGO, CA – SEPTEMBER 5, 2018 – Gene Biotherapeutics Inc. (formerly Taxus Cardium Pharmaceuticals Group Inc./trading symbol: CRXM) today announced that it has entered into an agreement with the U.S.-based Olaregen Therapeutix Inc. covering the sale of Excellagen® flowable dermal matrix for wound healing. Olaregen is a special purpose entity which was formed by an unaffiliated investment group to acquire and commercialize advanced wound healing therapeutics for multiple vertical markets. Gene Biotherapeutics retains the exclusive rights to develop and commercialize the Excellagen dermal matrix for wound healing in greater China, the Russian Federation and 11 other Eurasian countries within the Commonwealth of Independent States consistent with the indications for use as set forth in the Excellagen U.S. FDA 510(K) clearance letter and a US patent issued October 10, 2017."
I have refrained from asking you about this on a call out of respect. But since you have none for me, please prove I'm an idiot on this point.
Quote me a document I can read, not just something like your statement that you can convert the NUGX shares "whenever you want" vs. the 8K that says it's 270 days.
Just going on the facts...
I've read all the GNBT/NGIO 8-Ks and 10Ks/Qs in the last 3+ years. And I've also discussed this with some of the brightest shareholder minds involved in GNBT. No one understands it. Riddle me this, and I do hope you have a legitimate explanation that proves me wrong.
How can you offer China Excellagen rights in the event of a CV vaccine failure as part of the 2nd deal, when this is what I can find on the rights acquisition chain for Excellagen:
"SAN DIEGO, CA – SEPTEMBER 5, 2018 – Gene Biotherapeutics Inc. (formerly Taxus Cardium Pharmaceuticals Group Inc./trading symbol: CRXM) today announced that it has entered into an agreement with the U.S.-based Olaregen Therapeutix Inc. covering the sale of Excellagen® flowable dermal matrix for wound healing. Olaregen is a special purpose entity which was formed by an unaffiliated investment group to acquire and commercialize advanced wound healing therapeutics for multiple vertical markets. Gene Biotherapeutics retains the exclusive rights to develop and commercialize the Excellagen dermal matrix for wound healing in greater China, the Russian Federation and 11 other Eurasian countries within the Commonwealth of Independent States consistent with the indications for use as set forth in the Excellagen U.S. FDA 510(K) clearance letter and a US patent issued October 10, 2017."
I have refrained from asking you about this on a call out of respect. But since you have none for me, please prove I'm an idiot on this point.
Quote me a document I can read, not just something like your statement that you can convert the NUGX shares "whenever you want" vs. the 8K that says it's 270 days.
Just going on the facts...
(6)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼